PET/CT measures ENDO-HDR response, may let patients skip chemo

01/30/2013 | AuntMinnie.com (free registration)

PET/CT imaging can determine pathological response in postsurgery patients with stage II and III rectal cancer who underwent short high-dose-rate endorectal brachytherapy prior to surgery, according to results presented at a gastrointestinal cancers meeting. ENDO-HDR may allow patients to avoid chemotherapy before surgery, researchers said. They also hope the method will allow for nonoperative management of many patients.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA